Skip to main content
Ind-Swift Laboratories Ltd. logo

Ind-Swift Laboratories Ltd. — Investor Relations & Filings

Ticker · INDSWFTLAB ISIN · INE915B01019 LEI · 335800ZT8UFD9Y8ZMP56 BSE.NS Manufacturing
Open in API
Filings indexed 816 across all filing types
Latest filing 2026-05-28 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS INDSWFTLAB

About Ind-Swift Laboratories Ltd.

https://www.indswiftlabs.com

Ind-Swift Laboratories Ltd. is a global manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. The company focuses on research and development, process chemistry, and large-scale production across diverse therapeutic segments, including macrolide antibiotics, cardiovascular agents, antihistamines, antidiabetics, and antipsychotics. Operating multiple manufacturing facilities that adhere to international regulatory standards such as USFDA, EDQM, and PMDA, the organization provides high-quality chemical entities to the global market. Its core competencies lie in complex chemical synthesis and the development of cost-effective manufacturing processes for generic and specialty drug substances. The company maintains a strong emphasis on quality assurance and regulatory compliance to support its extensive portfolio of products distributed worldwide.

Recent filings

Filing Released Lang Actions
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is an intimation under SEBI Listing Regulations of allotment of equity shares under the Employee Incentive Scheme 2014, detailing the number of shares issued and the resulting change in paid-up capital. This constitutes a new share issue/capital change announcement, matching the Share Issue/Capital Change category.
2026-05-28 English
Intimation of allotment of 1,25,000 equity shares pursuant to ESOP, 2014.
Share Issue/Capital Change Classification · 92% confidence The document is an intimation under SEBI Listing Regulations notifying stock exchanges of the allotment of 125,000 equity shares under the Employee Incentive Scheme 2014, resulting in an increase in paid-up share capital. This is a regulatory announcement of a new share issue/capital change rather than an annual or interim report, audit, dividend notice, or management update. It directly pertains to a share issue event under an ESOP. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-28 English
Please refer attached pdf.
Regulatory Filings Classification · 80% confidence The document is a statutory compliance disclosure under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 concerning a ‘Statement of Deviation or Variation’ in the use of preferential issue proceeds. It is addressed to BSE/NSE and provides tables of utilization data for the quarter. It does not constitute an investor presentation, management report, audit report, or financial results release; rather, it is a routine regulatory announcement filing required by the stock exchanges. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-28 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 85% confidence The document is a regulatory compliance disclosure under Regulation 32 of SEBI’s Listing Obligations, providing the “Nil Statement on Deviation or Variation of Funds Raised through Preferential Issue” for the quarter ended March 31, 2026. It does not contain full financial statements or constitute an annual/interim report, earnings release, or management discussion. It is a mandated listing compliance announcement rather than the primary report itself, fitting the general “Regulatory Filings” category for compliance and disclosure notices.
2026-05-28 English
Please refer attached pdf.
Interim / Quarterly Report Classification · 78% confidence The document is the outcome of a Board meeting filed under SEBI Listing Regulations 30 & 33, providing the audited financial results for the quarter and year ended March 31, 2026 along with the auditor’s report and full financial statements (P&L, assets & liabilities, cash flows, notes). It contains substantive financial data and analysis for a period shorter than (and including) a full fiscal year, rather than merely announcing a report or sending a proxy statement. Hence it represents an Interim/Quarterly Report. FY 2026
2026-05-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is an outcome of a board meeting filed under SEBI Listing Regulations (Reg 30 & 33) which encloses the Audited Financial Results for the quarter and full year ended March 31, 2026, together with detailed financial statements (Balance Sheet, P&L, Cash Flow) and the independent auditor’s report. It is more than a brief earnings release and contains actual financial statements, so it qualifies as an Interim/Quarterly Report rather than a mere announcement or annual report. FY 2026
2026-05-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.